A new clinical trial listing involving gonadorelin was registered, with a status update recorded on September 3, 2026. The study, titled "Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer," is registered under identifier NCT07801898.
The trial is designated as Phase 2 and is currently listed with a status of not yet recruiting. This status indicates that participant enrollment has not yet begun as of the date reported.
According to the registration, the study is designed to evaluate a neoadjuvant treatment approach that combines endocrine therapy with chemotherapy in patients with ER-positive, HER2-negative breast cancer spanning stages I through III. No outcome data, efficacy findings, or safety results have been posted in connection with this listing.
Gonadorelin remains an approved compound, and this trial represents a new registered study rather than a change in its existing approval status. As the trial has not yet begun recruiting, no timeline for enrollment completion or results has been made available at this stage.
Readers interested in learning more about how gonadorelin is characterized in general can consult the compound overview for additional background and context.